-stock-6-month-chart.png)
Is ZSAN a good investment?
Historical index on US Stock Market : E "Should I invest in Zosano Pharma stock?" "Should I trade "ZSAN" stock today?" According to our live Forecast System, Zosano Pharma Corp stock is a bad long-term (1-year) investment*.
Why did ZSAN stock drop?
Fremont, CA-based Zosano ($ZSAN) delivered bitter news to its investors on Monday evening, tipping off the market that Eli Lilly ($LLY) had bowed out of their osteoporosis partnership while it had also decided to halt work on a daily dosing program.
Will ZSAN go up?
The 1 analysts offering 12-month price forecasts for Zosano Pharma Corp have a median target of 21.00, with a high estimate of 21.00 and a low estimate of 21.00. The median estimate represents a +7,677.78% increase from the last price of 0.27.
Is zosano Pharma going out of business?
Zosano Pharma has run out of road. After working to find a strategic alternative in the wake of the FDA's refusal to review its submission, the transdermal drug delivery specialist has now filed for paperwork for Chapter 11 bankruptcy.
What happened to Zosano Pharma?
Shares of Zosano Pharma Corp. lost nearly half of their value and hit a new all-time low on Thursday after the cash-strapped biopharmaceutical company filed for chapter 11 bankruptcy with plans to close up shop.
Will Qtrypta be approved?
Zosano filed for approval of Qtrypta in December 2019 and disclosed news of the FDA's acceptance of the submission for review the following March, resulting in a PDUFA date in October 2020. A late 2021 resubmission could see Qtrypta win FDA approval up to two years later than originally planned.
Why did VTVT stock go up?
vTv Therapeutics (VTVT) has strong positive catalysts in the medium term and the long term. Novavax (NVAX) looks poised to be boosted by an upcoming FDA approval of its coronavirus shot. Aileron (ALRN) has reported positive data and has a huge potential market Biotech stocks have tumbled in recent months and years.
What is Qtrypta?
Qtrypta is Zosano's proprietary investigational formulation of zolmitriptan delivered utilizing its proprietary transdermal microneedle system (the “System”) in development for the acute treatment of migraine.
Should I buy or sell Zosano Pharma stock right now?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zosano Pharma in the last year. There are currently 2 hold ratings and 1 b...
What is Zosano Pharma's stock price forecast for 2022?
3 analysts have issued 12-month price targets for Zosano Pharma's shares. Their forecasts range from $70.00 to $70.00. On average, they expect Zosa...
How has Zosano Pharma's stock performed in 2022?
Zosano Pharma's stock was trading at $16.45 at the start of the year. Since then, ZSAN shares have decreased by 96.6% and is now trading at $0.5576...
Are investors shorting Zosano Pharma?
Zosano Pharma saw a drop in short interest during the month of May. As of May 31st, there was short interest totaling 332,300 shares, a drop of 15....
When is Zosano Pharma's next earnings date?
Zosano Pharma is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022. View our earnings forecast for Zosano...
How were Zosano Pharma's earnings last quarter?
Zosano Pharma Co. (NASDAQ:ZSAN) announced its quarterly earnings data on Friday, May, 13th. The biotechnology company reported ($1.76) earnings per...
When did Zosano Pharma's stock split? How did Zosano Pharma's stock split work?
Shares of Zosano Pharma reverse split on the morning of Tuesday, April 12th 2022. The 1-35 reverse split was announced on Tuesday, April 12th 2022....
Who are Zosano Pharma's key executives?
Zosano Pharma's management team includes the following people: Mr. Steven Lo , Sr. VP of Operations, Pres, CEO & Director (Age 55, Pay $534.08k)...
Who are some of Zosano Pharma's key competitors?
Some companies that are related to Zosano Pharma include Bellicum Pharmaceuticals (BLCM) , Sonoma Pharmaceuticals (SNOA) , Medicure (MCUJF) , X...
What is Zosano Pharma's consensus rating and price target?
According to the issued ratings of 3 analysts in the last year, the consensus rating for Zosano Pharma stock is Hold based on the current 2 hold ra...
Do Wall Street analysts like Zosano Pharma more than its competitors?
Analysts like Zosano Pharma stock less than the stock of other Medical companies. The consensus rating for Zosano Pharma is Hold while the average...
Do MarketBeat users like Zosano Pharma more than its competitors?
MarketBeat users like Zosano Pharma stock more than the stock of other Medical companies. 71.20% of MarketBeat users gave Zosano Pharma an outperfo...
Is Zosano Pharma being downgraded by Wall Street analysts?
Over the previous 90 days, Zosano Pharma's stock had 1 downgrade by analysts.
Does Zosano Pharma's stock price have much upside?
According to analysts, Zosano Pharma's stock has a predicted upside of 161.23% based on their 12-month price targets.
What analysts cover Zosano Pharma?
Zosano Pharma has been rated by Maxim Group in the past 90 days.
When did Zosano Pharma buy signal 2021?
A buy signal was issued from a pivot bottom point on Monday, July 19, 2021, and so far it has risen 0.12%. Further rise is indicated until a new top pivot has been found. Zosano Pharma Corp has increased volume and follows the last lift in the price.
Does Zosano Pharma stock have sell signals?
The Zosano Pharma Corp stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock.
Is Zosano Pharma Corp stock A Buy?
Zosano Pharma Corp holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
Stock Price Forecast
The 2 analysts offering 12-month price forecasts for Zosano Pharma Corp have a median target of 1.50, with a high estimate of 2.00 and a low estimate of 1.00. The median estimate represents a +1,143.78% increase from the last price of 0.12.
Analyst Recommendations
The current consensus among 2 polled investment analysts is to Buy stock in Zosano Pharma Corp. This rating has held steady since February, when it was unchanged from a Buy rating. Move your mouse over past months for detail
How does MarketBeat calculate stock ratings?
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Does Zosano Pharma outperform?
MarketBeat users like Zosano Pharma stock more than the stock of other Medical companies. 73.19% of MarketBeat users gave Zosano Pharma an outperform vote while medical companies recieve an average of 67.31% outperform votes by MarketBeat users.
